Abstract
The effect of cyclophosphamide on MSV-H oncogensis and the immune response of young mice has been investigated. A single, sublethal dose (100 and 50 mg/kg of cyclophosphamide) in 8-day-old mice given 24 h before or after MSV-H infection led to an earlier and lower incidence of tumours in comparison with controls infected only with MSV-H. The protective effect of cyclophosphamide, and the mechanism of action of both cyclophosphamide and MSV-H on the target cells, mesenchymal cells in rapid replication, as well the immunological implications of the findings are discussed.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bremberg S. The influence of host factors on cyclophosphamide treatment of Moloney virus-induced lymphomas. Eur J Cancer. 1970 Aug;6(4):277–286. doi: 10.1016/0014-2964(70)90091-5. [DOI] [PubMed] [Google Scholar]
- Brock N., Hohorst H. J. Metabolism of cyclophosphamide. Cancer. 1967 May;20(5):900–904. doi: 10.1002/1097-0142(1967)20:5<900::aid-cncr2820200552>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
- Chesterman F. C., Harvey J. J., Dourmashkin R. R., Salaman M. H. The pathology of tumors and other lesions induced in rodents by virus derived from a rat with Moloney leukemia. Cancer Res. 1966 Aug;26(8):1759–1768. [PubMed] [Google Scholar]
- Dumont F. Destruction and regeneration of lymphocyte populations in the mouse spleen after cyclophosphamide treatment. Int Arch Allergy Appl Immunol. 1974;47(1):110–123. doi: 10.1159/000231206. [DOI] [PubMed] [Google Scholar]
- FOLEY G. E., FRIEDMAN O. M., DROLET B. P. Studies on the mechanism of action of cytoxan. Evidence of activation in vivo and in vitro. Cancer Res. 1961 Jan;21:57–63. [PubMed] [Google Scholar]
- Fefer A. Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res. 1969 Dec;29(12):2177–2183. [PubMed] [Google Scholar]
- HARVEY J. J. AN UNIDENTIFIED VIRUS WHICH CAUSES THE RAPID PRODUCTION OF TUMOURS IN MICE. Nature. 1964 Dec 12;204:1104–1105. doi: 10.1038/2041104b0. [DOI] [PubMed] [Google Scholar]
- Harvey J. J., East J. The murine sarcoma virus (MSV). Int Rev Exp Pathol. 1971;10:265–360. [PubMed] [Google Scholar]
- Lagrange P. H., Mackaness G. B., Miller T. E. Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide. J Exp Med. 1974 Jun 1;139(6):1529–1539. doi: 10.1084/jem.139.6.1529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Levij I. S., Rwomushana J. W., Polliack A. Effect of topical cyclophosphamide, methotrexate and vinblastine on 9,10-dimethyl-1,2-benzanthracene (DMBA)--carcinogenesis in the hamster cheek pouch. Eur J Cancer. 1970 Jun;6(3):187–193. doi: 10.1016/0014-2964(70)90021-6. [DOI] [PubMed] [Google Scholar]
- Moore M., Williams D. E. Contribution of host immunity to cyclophosphamide therapy of a chemically-induced murine sarcoma. Int J Cancer. 1973 Mar 15;11(2):358–368. doi: 10.1002/ijc.2910110213. [DOI] [PubMed] [Google Scholar]
- Turk J. L. Evidence for a preferential effect of cyclophosphamide on B-cells. Proc R Soc Med. 1973 Aug;66(8):805–808. doi: 10.1177/003591577306600837. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Turk J. L., Poulter L. W. Effects of cyclophosphamide on lymphoid tissues labelled with 5-iodo-2-deoxyuridine- 125 I and 51 Cr. Int Arch Allergy Appl Immunol. 1972;43(4):620–629. doi: 10.1159/000230874. [DOI] [PubMed] [Google Scholar]
- Winkelstein A. Mechanisms of immunosuppression: effects of cyclophosphamide on cellular immunity. Blood. 1973 Feb;41(2):273–284. [PubMed] [Google Scholar]
- van Putten L. M., Lelieveld P. Factors determining cell killing by chemotherapeutic agents in vivo. I. Cyclophosphamide. Eur J Cancer. 1970 Aug;6(4):313–321. doi: 10.1016/0014-2964(70)90096-4. [DOI] [PubMed] [Google Scholar]